《新股消息》康寧傑瑞製藥(09966.HK)料PD-L1產品明年上半年可申請在內地上市
康寧傑瑞製藥(09966.HK)首席執行官徐霆出席上市儀式後表示,公司的PD-L1產品希望明年上半年可申請在內地上市,如順利,明年或2021年可獲上市許可。針對內地藥物「帶量採購」的政策,他認為由於公司主要做創新藥,加上定位全球市場,故關係並不大,但創新藥能否被納入醫保則有影響,之前國內亦有PD-L1藥物進入醫保,而其價格仍有利潤空間,因此並不擔心。
在海外拓展方面,他指公司雙抗產品在全球競爭力處於前列,現時在很多腫瘤實驗亦有良好的初步成果,故認為公司具前景。被問及何時扭虧,首席財務官帥琪指出藥品將來的盈利難在現階段作預測,而中國政策有不斷改變的地方,公司近一、兩年仍會保持投入,故仍會錄虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.